SEC Filings

Form 10-Q
PROTAGONIST THERAPEUTICS, INC filed this Form 10-Q on 05/09/2018
Document Outline
Entire Document (3814.3 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - PROTAGONIST THERAPEUTICS, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - PROTAGONIST THERAPEUTICS, INC.
Page 5 - PROTAGONIST THERAPEUTICS, INC.
Page 6 - PROTAGONIST THERAPEUTICS, INC.
Page 7 - PROTAGONIST THERAPEUTICS, INC.
Page 8 - PROTAGONIST THERAPEUTICS, INC.
Page 9 - PROTAGONIST THERAPEUTICS, INC.
Page 10 - PROTAGONIST THERAPEUTICS, INC.
Page 11 - PROTAGONIST THERAPEUTICS, INC.
Page 12 - PROTAGONIST THERAPEUTICS, INC.
Page 13 - PROTAGONIST THERAPEUTICS, INC.
Page 14 - PROTAGONIST THERAPEUTICS, INC.
Page 15 - PROTAGONIST THERAPEUTICS, INC.
Page 16 - PROTAGONIST THERAPEUTICS, INC.
Page 17 - PROTAGONIST THERAPEUTICS, INC.
Page 18 - PROTAGONIST THERAPEUTICS, INC.
Page 19 - PROTAGONIST THERAPEUTICS, INC.
Page 20 - PROTAGONIST THERAPEUTICS, INC.
Page 21 - PROTAGONIST THERAPEUTICS, INC.
Page 22 - PROTAGONIST THERAPEUTICS, INC.
Page 23 - PROTAGONIST THERAPEUTICS, INC.
Page 24 - PROTAGONIST THERAPEUTICS, INC.
Page 25 - ITEM 2.MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 26 - N/A
Page 27 - Janssen License and Collaboration Agreement
Page 28 - N/A
Page 29 - General and Administrative Expenses
Page 30 - Results of Operations
Page 31 - General and Administrative Expenses
Page 32 - N/A
Page 33 - Cash Flows from Operating Activities
Page 34 - Contractual Obligations and Other Commitments
Page 35 - ITEM 4.CONTROLS AND PROCEDURES
Page 36 - Risks Related to Our Financial Position and Capital Requirements
Page 37 - N/A
Page 38 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 39 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 40 - Risks Related to Our Business and Industry
Page 41 - N/A
Page 42 - If Janssen does not elect to continue the development of PTG-200 through an Opt-In Election, our bus
Page 43 - N/A
Page 44 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 45 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 46 - Our research and development strategy for our lead product candidates relies in large part on clinic
Page 47 - Our product candidates may cause undesirable side effects or have other properties impacting safety
Page 48 - We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third par
Page 49 - We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance
Page 50 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 51 - We may not be successful in obtaining or maintaining development and commercialization collaboration
Page 52 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 53 - We have not yet negotiated our agreement with Janssen specifying all of the terms of our Co-Detailin
Page 54 - We currently have no marketing and sales organization. To the extent any of our peptide-based produc
Page 55 - We have focused our limited resources to pursue particular product candidates and indications, and c
Page 56 - If we fail to comply with state and federal healthcare regulatory laws, we could face substantial pe
Page 57 - N/A
Page 58 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 59 - N/A
Page 60 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 61 - We may need to expand the size of our organization, and we may experience difficulties in managing t
Page 62 - Our insurance policies are expensive and only protect us from some business risks, which will leave
Page 63 - Our employees, independent contractors, principal investigators, consultants and vendors may engage
Page 64 - We currently conduct, and intend to continue to conduct, a substantial portion of the clinical trial
Page 65 - Our headquarters and certain of our data storage facilities are located near known earthquake fault
Page 66 - Risks Related to Our Intellectual Property
Page 67 - N/A
Page 68 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 69 - Any issued patents covering our product candidates, including any patent that may issue as a result
Page 70 - The lives of any patents issued as a result of our pending or future patent applications may not be
Page 71 - Third party claims of intellectual property infringement may prevent or delay our drug discovery and
Page 72 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 73 - Intellectual property disputes could cause us to spend substantial resources and distract our person
Page 74 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 75 - We may be subject to claims that our employees, consultants or independent contractors have wrongful
Page 76 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 77 - Any collaboration arrangements that we may enter into in the future may not be successful, which cou
Page 78 - Risks Related to Ownership of our Common Stock
Page 79 - N/A
Page 80 - Volatility in our share price could subject us to securities class action litigation.*
Page 81 - We are obligated to develop and maintain proper and effective internal controls over financial repor
Page 82 - Future sales of our common stock may depress our share price.*
Page 83 - We have incurred and will continue to incur increased costs as a result of operating as a public com
Page 84 - Any changes to existing accounting pronouncements or taxation rules or practices may cause adverse f
Page 85 - Claims for indemnification by our directors and officers may reduce our available funds to satisfy s
Page 86 - Provisions in our corporate charter documents could make an acquisition of us more difficult and may
Page 87 - The recently passed comprehensive tax reform bill could adversely affect our business and financial
Page 88 - ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Page 89 - EXHIBIT INDEX
Page 90 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer